Biogen

Activities: Pharmaceutical

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Manufacturing

Samsung Biologics acquires full ownership of Biogen joint venture

Biogen initially invested in a 15% stake in Samsung Bioepis when it was established as a joint venture in 2012
Research & Development

Eisai and Biogen announce Phase IV Alzheimer's study design

The companies will be evaluating the long-term effectiveness and safety data of Biogen's Alzheimer's therapy, Aduhelm
Finance

Fujifilm to acquire manufacturing site from Biogen

Japanese manufacturing giant aims to accelerate the growth of its biologics CDMO business
Media

Biogen and Samsung Bioepis launch Imraldi in Europe

The product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialised by Biogen across Europe
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Media

Biogen and Neurimmune announce option exercise for Aducanumab

The transaction will increase the profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune
Subscribe now